Changlu Hu

发表

The efficient circulating immunoscore predicts prognosis of patients with advanced gastrointestinal cancer

Yan Tang, Hanlin Qin, Yamei Zhao, 2022, World Journal of Surgical Oncology.

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Jiyan Liu, J. Ying, X. Yao, 2020, Clinical Cancer Research.

Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study

W. Wang, Jinsheng Hong, Liangfang Shen, 2022, The Lancet regional health. Western Pacific.

LncRNA MCM3AP-AS1 promotes breast cancer progression via modulating miR-28-5p/CENPF axis.

Qi Chen, Jiang Zhu, Huachao Xu, 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial

Bihong Zhan, Yu-fei Zhao, Jin Huang, 2022, Frontiers in Pharmacology.

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)

D. Zhong, Yanqiu Zhao, Yun-peng Yang, 2022, EClinicalMedicine.

A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.

Jiyan Liu, X. Yao, Yanxia Shi, 2019, Journal of Clinical Oncology.

Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer

J. Ying, Yanxia Shi, Y. Ling, 2023, Journal of the National Cancer Center.

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

H. Pan, Yanqiu Zhao, P. Xing, 2021, Cancer communications.

Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer

Ming Yan, Bing-he Xu, Huiping Li, 2022, Cancer Research.

An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).

Jiyan Liu, Shiying Yu, J. Ying, 2021 .

High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma.

Yan Tang, Suyi Li, Kehai Feng, 2021, Journal of gastrointestinal oncology.

Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

Yanxia Shi, Y. Ling, Lin Wang, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Y. Wang, Ying Cheng, Bing-he Xu, 2023, The Lancet. Oncology.

A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma.

W. Han, C. Fu, Changlu Hu, 2024, European journal of cancer.